文献速递神经MR

影像学与液体活检鉴别胶质瘤真性进展与假性进展:当前进展与挑战

Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges.
PubMed 文献 · Acad Radiol · 2024-04-12

本综述讨论用于鉴别胶质瘤真性进展(TP)与假性进展(PsP)的影像技术(如MR扩散成像、灌注加权成像)和液体活检方法,指出这些方法在刻画肿瘤组织特性、识别肿瘤来源标志物方面有效,但敏感度不一致、缺乏标准化协议及生物学变异性等问题阻碍其常规临床应用,需进一步研究验证。

要点

  • MR扩散成像和灌注加权成像可刻画肿瘤组织特性,为判断胶质瘤行为提供有价值信息。
  • 液体活检通过生物体液中的肿瘤来源标志物,可无创地反映肿瘤演化。
  • 上述方法敏感度不一致、缺乏跨平台标准化协议,鉴别TP与PsP的准确性受限。

核心结论

  • 先进影像技术和液体活检在鉴别胶质瘤TP与PsP方面有应用潜力,但常规临床应用前仍存在差距,需进一步研究开发和验证这些方法。

研究设计与样本

  • 综述,综合现有文献,讨论用于鉴别胶质瘤真性进展与假性进展的影像技术(MR扩散成像、灌注加权成像MRI)和液体活检。

诊断标准与关键数值

  • MR扩散成像和灌注加权成像MRI已被证明可有效描绘肿瘤组织特性,为胶质瘤行为提供有价值信息。
  • 液体活检已成为识别生物体液中肿瘤来源标志物的有力工具,可无创地反映肿瘤演化。

临床应用与阅片要点

  • 原文结论指出这些方法有应用潜力,但常规临床应用前仍有差距,需进一步研究开发和验证。

局限性

  • 这些方法的敏感度仍不一致,使TP与PsP的准确鉴别复杂化。
  • 缺乏跨平台的标准化协议,妨碍比较的可靠性。
  • 固有的生物学变异性增加了数据解读的复杂性。
  • 常规临床应用前仍存在差距,需进一步研究开发和验证这些方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Gliomas are aggressive brain tumors with a poor prognosis. Assessing treatment response is challenging because magnetic resonance imaging (MRI) may not distinguish true progression (TP) from pseudoprogression (PsP). This review aims to discuss imaging techniques and liquid biopsies used to distinguish TP from PsP.

MATERIALS AND METHODS: This review synthesizes existing literature to examine advances in imaging techniques, such as magnetic resonance diffusion imaging (MRDI), perfusion-weighted imaging (PWI) MRI, and liquid biopsies, for identifying TP or PsP through tumor markers and tissue characteristics.

RESULTS: Advanced imaging techniques, including MRDI and PWI MRI, have proven effective in delineating tumor tissue properties, offering valuable insights into glioma behavior. Similarly, liquid biopsy has emerged as a potent tool for identifying tumor-derived markers in biofluids, offering a non-invasive glimpse into tumor evolution. Despite their promise, these methodologies grapple with significant challenges. Their sensitivity remains inconsistent, complicating the accurate differentiation between TP and PSP. Furthermore, the absence of standardized protocols across platforms impedes the reliability of comparisons, while inherent biological variability adds complexity to data interpretation.

CONCLUSION: Their potential applications have been highlighted, but gaps remain before routine clinical use. Further research is needed to develop and validate these promising methods for distinguishing TP from PsP in gliomas.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Li K, Zhu Q, Yang J, et al. Imaging and Liquid Biopsy for Distinguishing True Progression From Pseudoprogression in Gliomas, Current Advances and Challenges. Acad Radiol. 2024. PMID: 38614827. doi:10.1016/j.acra.2024.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。